BASF Nears Record High as €12bn Dividend Pledge Meets Agri-Tech Shift

BASF stock rebounds 21% YTD to near 52-week high, fueled by quantum computing breakthroughs, a new in-house biological crop protection facility, and a €12B dividend roadmap for 2025-2028.

BASF's stock is inching closer to its 52-week peak, supported by two distinct strategic thrusts: a leap in quantum computing capabilities and a major in-house push into biological crop protection. At €54.21, the share price sits just shy of the April high of €54.70, having rallied more than 21% since the start of the year.

The rebound rests on more than market sentiment. The group has laid out a clear payout roadmap for 2025 through 2028, targeting total dividends of roughly €12 billion. That ambition hinges on free cash flow generation, with a forecast of €1.3 billion for 2025 and a range between €1.5 billion and €2.3 billion for 2026. The numbers signal that BASF intends to fund distributions without eating into its capital base.

Alongside the dividend story, the company is making tangible progress in a technology often dismissed as distant. Its quantum computing initiative, running since 2017, recently achieved 60-qubit simulations on NVIDIA's Eos H100 supercomputer — up from a previous ceiling of 24 qubits on standard graphics processors. The simulations focus on NTA molecules used in wastewater treatment, leveraging NVIDIA CUDA Quantum. More qubits mean sharper modelling of chemical reactions, which could eventually translate into production and development efficiencies.

On the agricultural side, BASF has opened a BioHub at its Ludwigshafen headquarters, a fermentation facility that marks a shift from outsourcing to self-sufficiency in biological active ingredients. The plant, which cost a high double-digit million euro sum, is already producing Bacillus amyloliquefaciens for the fungicide Serifel and the core component of the insecticide Inscalis, derived from Penicillium coprobium. The process uses glucose and other renewable raw materials, strengthening supply chain resilience. The BioHub is designed to be scalable as new active ingredients emerge from the pipeline.

This move aligns with broader structural change. Agricultural Solutions has operated as a standalone segment since May 2026, paving the way for a planned Frankfurt IPO in 2027. The division generated €9.6 billion in revenue in 2025, and the global biological crop protection market is expanding — a tailwind BASF wants to capture directly.

Group-level earnings tell a quieter story. First-quarter 2026 EBITDA before special items slipped to €2.4 billion from €2.5 billion a year earlier, weighed by currency effects and slightly lower prices. The company maintains its full-year forecast: EBITDA between €6.2 billion and €7.0 billion, and free cash flow in the €1.5 billion to €2.3 billion range.

Insider activity has added a layer of confidence. Board member Dr. Dirk Elvermann purchased BASF shares worth roughly €45,800 at a price of €50.91. With the stock now at €54.01 — about 21% above where it stood a year ago — that trade has already paid off on paper.

The broader chemicals sector remains uneven. Bayer surprised positively in crop science, while Brenntag felt the pinch from geopolitical tensions and lower selling prices. BASF has largely shrugged off that headwind. Its relative strength index sits at 70.5, a reading that warns of stretched conditions, and the stock trades roughly 17% above its 200-day moving average. Those technical signals reflect expectations that management can balance future-focused investments with the promise of reliable payouts. The real test arrives when the company delivers concrete free cash flow numbers for 2025.